



Cite this: *Biomater. Sci.*, 2025, **13**, 1831

## Pentablock thermoresponsive hydrogels for chemotherapeutic delivery in a pancreatic cancer model†

Amr Elsherbeny, <sup>‡a,b,c</sup> Hulya Bayraktutan, <sup>a,c,d</sup> Nurcan Gumus, <sup>a,c,e,f</sup> Phoebe McCrorie,<sup>c</sup> Andres Garcia-Sampedro, <sup>g</sup> Shreeya Parmar, <sup>b</sup> Alison A. Ritchie, <sup>b</sup> Marian Meakin,<sup>b</sup> Umut Can Oz, <sup>a,h</sup> Ruman Rahman, <sup>c</sup> Jennifer C. Ashworth, <sup>c,i</sup> Anna M. Grabowska,<sup>b,c</sup> Cara Moloney <sup>‡a,c</sup> and Cameron Alexander <sup>\*a</sup>

The design of biodegradable and thermoresponsive polymeric hydrogels with tuneable properties holds immense promise for localised and sustained drug delivery. In this study, we designed and synthesised a library of novel pentablock copolymers, incorporating poly(D,L-lactide) (PLA) into methoxypoly(ethylene glycol)-poly(*ε*-caprolactone)-methoxypoly(ethylene glycol) (mPEG-PCL-mPEG, or PECE) hydrogels to enhance the hydrolytic degradation and drug release profiles. A pentablock copolymer, methoxypoly(ethylene glycol)-*b*-poly(D,L lactide)-*b*-poly(*ε*-caprolactone)-*b*-poly(D,L lactide)-*b*-methoxypoly(ethylene glycol) (mPEG-PLA-PCL-PLA-mPEG, or PELCLE), was selected based on its thermoresponsive sol–gel transition behaviour at a physiologically relevant temperature (37 °C). Physicochemical characterisation revealed that both PECE and PELCLE hydrogels self-assembled into micellar structures, with PELCLE exhibiting smaller micellar sizes compared to PECE. The incorporation of PLA led to reduced hydrogel stiffness, enhanced degradability, and decreased swelling compared to PECE. *In vitro* drug release studies demonstrated that both hydrogels exhibited sustained release of various anti-cancer drugs, with PELCLE generally showing slower release kinetics, highlighting its potential for prolonged drug delivery. For potential pancreatic cancer applications, we evaluated the biocompatibility and therapeutic efficacy of PELCLE hydrogels loaded with gemcitabine and oxaliplatin (GEMOX). *In vitro* and *in vivo* studies demonstrated safety and some anti-tumour efficacy of GEMOX-loaded PELCLE compared to free drug administration, attributed to enhanced tumour retention and sustained drug release. These findings highlight the potential of the PELCLE hydrogel as a versatile and effective local drug delivery platform for the treatment of pancreatic cancer and other solid tumours, warranting further investigation towards its clinical translation.

Received 5th December 2024,

Accepted 31st January 2025

DOI: 10.1039/d4bm01629g

rsc.li/biomaterials-science

<sup>a</sup>Division of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK.

E-mail: amr.elsherbeny@nottingham.ac.uk, a.elsherbeny@mesox.co.uk, hulya.bayraktutan@hacettepe.edu.tr, nurcan.gumus@bakircay.edu.tr, cameron.alexander@nottingham.ac.uk

<sup>b</sup>Ex Vivo Cancer Pharmacology Centre, Translational Medical Sciences, Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK.

E-mail: alison.ritchie@nottingham.ac.uk, shreeya.parmar@nottingham.ac.uk, marian.meakin@nottingham.ac.uk, anna.grabowska@nottingham.ac.uk

<sup>c</sup>Biodiscovery Institute, School of Medicine, University of Nottingham, Nottingham, NG7 2UH, UK. E-mail: ruman.rahman@nottingham.ac.uk,

jennifer.ashworth@nottingham.ac.uk, cara.moloney@nottingham.ac.uk

<sup>d</sup>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Hacettepe University, Ankara 06100, Türkiye

<sup>e</sup>Department of Medical Biology, Faculty of Medicine, Izmir Bakircay University, Izmir, Türkiye

<sup>f</sup>Department of Medical Pharmacology, Faculty of Medicine, Izmir Bakircay University, Izmir, Türkiye

<sup>g</sup>Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Dr, Cambridge CB3 0AS, UK. E-mail: ag2421@cam.ac.uk

<sup>h</sup>Department of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara 06560, Türkiye. E-mail: umutcanoz@ankara.edu.tr

<sup>i</sup>School of Veterinary Medicine & Science, University of Nottingham, Sutton Bonington Campus, Leicestershire, LE12 5RD, UK

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d4bm01629g>

‡ AE and CM contributed equally in this work.



## Introduction

Systemic chemotherapy, while effective, often results in significant toxicity to healthy tissues, limiting clinically administered doses.<sup>1–3</sup> This has spurred the development of local drug delivery systems, aiming to achieve sustained and targeted release, thereby minimizing systemic toxicity while maintaining therapeutic efficacy at the target site.<sup>4,5</sup> Biodegradable, thermo-responsive hydrogels have emerged as a promising approach due to their ability to deliver a variety of therapeutic agents, including drugs, proteins, and cell carriers, and their potential for use in tissue engineering.<sup>6–10</sup> These injectable hydrogels offer several advantages, including minimally invasive administration and localised drug delivery.<sup>11–13</sup> Furthermore, their ability to undergo gelation at body temperature enables depot drug release, reducing administration frequency and improving patient quality of life.<sup>14–16</sup> This sustained release also protects the therapeutic agent from rapid metabolism and elimination, potentially extending its efficacy.<sup>17</sup>

Amphiphilic thermosensitive polymers are particularly attractive due to their ability to undergo sol–gel transitions *via* physical crosslinking and micellar aggregation above a critical concentration, under mild conditions.<sup>3,18–20</sup> This eliminates the need for potentially toxic chemical crosslinkers or pH adjustments, offering a safer alternative to chemical gelation. Among these, methoxypoly(ethylene glycol)-poly( $\epsilon$ -caprolactone)-methoxypoly(ethylene glycol) (mPEG-PCL-mPEG, or PECE) has been considered as a promising candidate for various healthcare applications as it is composed of polymers that have been used clinically.<sup>21–23</sup> PECE-based hydrogels have been explored as drug delivery systems for diverse therapeutic agents in conditions such as ocular inflammation, bacterial infections, and bone regeneration.<sup>22–24</sup>

The gelation behaviour and rheological properties of PECE polymers are intrinsically linked to the balance between hydrophilic and hydrophobic components, with factors like chemical composition, block length, and molecular weight of PCL and PEG influencing the sol–gel transition.<sup>23,25</sup> Moreover, the hydrophobic nature of PCL units significantly impacts hydrogel degradation rates, typically leading to prolonged *in vivo* retention (2–3 years).<sup>26</sup> To address this, we introduced PLA blocks into PECE using a systematic approach, creating an ABCBA pentablock polymer methoxypoly(ethylene glycol)-*b*-poly( $\epsilon$ -caprolactone) poly(<sub>D,L</sub> lactide)-*b*-poly( $\epsilon$ -caprolactone)-*b*-methoxypoly(ethylene glycol) (mPEG-PCL-PLA-PCL-mPEG). We also synthesised an analogue methoxypoly(ethylene glycol)-*b*-poly(<sub>D,L</sub> lactide)-*b*-poly( $\epsilon$ -caprolactone)-*b*-poly(<sub>D,L</sub> lactide)-*b*-methoxypoly(ethylene glycol) (mPEG-PLA-PCL-PLA-mPEG), with the aim of enhancing its hydrolytic degradation as a result of the faster degradation times of PLA as compared to PCL blocks.<sup>27</sup> Additionally, we hypothesised that the inclusion of PLA blocks would modulate hydrogel swelling and water uptake, potentially leading to modified drug release profiles.<sup>28</sup>

We made a series of pentablock copolymers through the incorporation of PLA blocks into PECE polymers, and from these selected a polymer (designated as PELCLE) which was

freely soluble in aqueous buffer below 20 °C but which formed a viscous hydrogel-like material at 37 °C. DLS and TEM were used to characterize material structures and SEM to examine macro-structural changes. Additionally, we evaluated *in vitro* swelling behaviour, hydrogel degradation, and *in vitro* drug release profiles of various chemotherapeutic agents with diverse cLogP values (oxaliplatin, gemcitabine, doxorubicin and olaparib), correlating release mechanisms with mathematical models.

We then explored PELCLEs for localised and sustained GEMOX delivery in pancreatic cancer models. Tolerability of gel formulations was assessed *in vitro* using pancreatic cancer cell lines and *in vivo* using PANC1-FLuc xenograft mouse models. We confirmed the synergistic cytotoxic effects of GEMOX at various molar ratios and investigated the impact of GEMOX loading on PELCLE properties and drug release profile. To evaluate tumour retention, we compared the release profile of the hydrophilic fluorescent dye Cy5.5 from PELCLE hydrogels to free Cy5.5 in subcutaneous xenograft models. Finally, the anti-tumour efficacy of GEMOX-loaded PELCLE hydrogels was compared to free GEMOX, both *in vitro* using PANC-FLuc cells and *in vivo* in subcutaneous xenograft PANC-FLuc mouse models.

## Materials and methods

### Materials

Mono-methoxy poly(ethylene glycol) (mPEG, 500 g mol<sup>-1</sup>),  $\epsilon$ -caprolactone ( $\epsilon$ CL, 97%), tin(II) 2-ethylhexanoate (SnOct<sub>2</sub>, 92.5–100%), hexamethylene diisocyanate (HMDI,  $\geq$ 99%), dulbecco's modified eagle media (DMEM), trypsin-EDTA solution, fetal bovine serum (FBS), L-glutamine, and all deuterated solvents were purchased from Sigma-Aldrich. Gemcitabine hydrochloride ( $\geq$ 98%) and oxaliplatin ( $\geq$ 98%) were obtained from Biosynth. Cyanine5.5 (Cy5.5) alkyne was purchased from Lumiprobe. PrestoBlue™ was purchased from Thermo Fisher Scientific. Human pancreatic adenocarcinoma cells (PANC-1) were obtained from the European Collection of Authenticated Cell Cultures (ECACC) and lentivirally transduced in house with the Firefly Luciferase gene (FLuc). All solvents were purchased from Fisher Scientific. Ki67 (ab16667) primary antibody was purchased from Abcam. Normal Goat Serum (10098792) was purchased from Gibco. Dako REAL EnVision detection system (peroxidase/DAB), wash buffer and Dako REAL peroxidase-blocking solution were purchased from Agilent. All chemicals were used as received unless otherwise stated.

### Polymer synthesis and characterisation

**Synthesis of mPEG-*b*-PCL-HMDI-PCL-*b*-mPEG (PECE) tri-block polymer.** mPEG-*b*-PCL-HMDI-PCL-*b*-mPEG, or PECE tri-block copolymer was synthesised *via* ring-opening copolymerisation of  $\epsilon$ -caprolactone ( $\epsilon$ CL) initiated by mPEG, using stannous octoate as a catalyst and hexamethylene diisocyanate (HMDI) as a crosslinker, as previously described.<sup>21</sup> Briefly, mPEG (5 g, 0.010 mol, 500 g mol<sup>-1</sup>) was dissolved in anhydrous toluene (50 mL) and subjected to azeotropic distillation



to remove residual moisture.  $\epsilon$ CL (10.5 g, 0.0919 mol) was added to the reaction mixture, which was then stirred at 120 °C under nitrogen until homogeneous.  $\text{Sn}(\text{Oct})_2$  (77.4 mg, 0.0002 mol) in  $\text{CH}_2\text{Cl}_2$  (2 mL) was added to initiate polymerisation. The reaction proceeded overnight under nitrogen, and its progress was monitored by  $^1\text{H}$  NMR and GPC to ensure complete monomer conversion. Subsequently, the reaction temperature was lowered to 80 °C, and after 30 minutes, HMDI (1.68 g, 0.01 mol) was added. The reaction continued for an additional 24 hours. The resulting pale-yellow viscous product was dissolved in  $\text{CH}_2\text{Cl}_2$ , precipitated in cold hexane, and centrifuged (5 min, 4200g). The isolated copolymer was dried under vacuum at 30 °C overnight, yielding a white powder which was analysed by FT-IR, GPC, and  $^1\text{H}$  NMR.

**Synthesis of pentablock copolymers.** mPEG-*b*-PLA-*b*-PCL-HMDI-PCL-*b*-PLA-mPEG and mPEG-*b*-PCL-*b*-PLA-HMDI-PLA-*b*-PCL-mPEG pentablock copolymers were synthesised *via* sequential ring-opening copolymerisation, employing varying ratios of poly( $\epsilon$ -caprolactone) (PCL) to poly(*D,L*-lactide) (PLA) as detailed in Table 1.

The synthesis began with the azeotropic distillation of mPEG (5 g, 0.010 mmol, 500 g mol<sup>-1</sup>) in anhydrous toluene at 50 °C. Subsequently, predetermined amounts of *D,L*-lactide or  $\epsilon$ -caprolactone were added to the reaction mixture, which was then stirred at 120 °C under a nitrogen atmosphere until a homogeneous solution was obtained. Polymerisation was initiated by the addition of  $\text{Sn}(\text{Oct})_2$  (52.2 mg, 0.0004 mmol) dissolved in  $\text{CH}_2\text{Cl}_2$ . The reaction was allowed to proceed overnight, and complete monomer conversion to the corresponding mPEG-PLA or mPEG-PCL diblock copolymers was confirmed by  $^1\text{H}$  NMR analysis.

To synthesize the triblock copolymers,  $\epsilon$ -caprolactone or *D,L*-lactide was added to the respective mPEG-PLA or mPEG-PCL diblock solutions, and the polymerisation process was repeated as described above. For the final pentablock copolymer formation, the reaction temperature was lowered to 80 °C, HMDI (1.68 g, 0.01 mmol) was introduced and the reaction was maintained for an additional 24 hours. The resulting pale-yellow viscous product was dissolved in  $\text{CH}_2\text{Cl}_2$ , precipitated in cold hexane, and subsequently centrifuged (5 min, 4200g). The

isolated copolymer was then dried under vacuum at 30 °C overnight and analysed by FT-IR, GPC, and  $^1\text{H}$  NMR.

**Gel permeation chromatography (GPC).** The analysis of samples was conducted using a PL-50 instrument equipped with a refractive index (RI) detector. Two Agilent PLgel 5  $\mu\text{m}$  MIXED-D columns and a 5  $\mu\text{m}$  PLgel guard column were employed for separation. The mobile phase consisted of DMF with a 0.1% (w/v) LiBr additive. The samples were processed at a flow rate of 1 mL min<sup>-1</sup>, and the temperature was maintained at 50 °C, controlled by a column oven. Average molar mass ( $M_{\text{wt}}$ ), Number Average Molecular Weight ( $M_{\text{n}}$ ), and polydispersity ( $D$ ) were determined by referencing poly(methyl methacrylate) standards (Agilent EasyVials) with a specified range of 500–955 550 g mol<sup>-1</sup>. The calibration was achieved using Agilent EasyVial calibrants, incorporating a cubic function to establish a correlation between retention time and molar mass. The Cirrus GPC software was employed for this purpose. Polymer samples were made by dissolving 2 mg mL<sup>-1</sup> pure polymer in 1 mL DMF + 0.1% LiBr. 100  $\mu\text{L}$  samples were injected and eluted at 1 mL min<sup>-1</sup> for 30 min.

**ATR-FTIR characterisation.** The FTIR spectra of all polymers were analysed using a BioRad FTS 6000 FTIR Spectrometer, which covers the range of 4000–400 cm<sup>-1</sup>. An attenuated total reflectance (ATR) accessory was utilised to assess the sample surface. The polymers were placed directly onto the ATR surface for analysis, employing DTGS optics at 5 kHz and a resolution of 2 cm<sup>-1</sup>.

**NMR spectroscopy.**  $^1\text{H}$  NMR spectra were recorded on a Bruker DPX 400 UltraShield™ Spectrometer (400 MHz) using deuterated solvents. Spectra were processed with MestReNova 9.0.1 software. All chemical shifts are reported in ppm ( $\delta$ ) relative to the chemical shifts of deuterated solvents. Multiplicities are described with the following abbreviations: s = singlet, d = doublet, t = triplet, m = multiplet.

### Evaluation of hydrogel formation in synthesized polymers and selection of an optimum polymer

**Preparation of thermoresponsive hydrogels.** All thermoresponsive hydrogels were prepared by subjecting the polymers to a temperature cycling approach until a clear and hom-

**Table 1** Characteristics of synthesised copolymers

Polymer	Block orientation	Total LA units	Total $\epsilon$ CL units	LA (mol)	$\epsilon$ CL (mol)	$D$	GPC $M_{\text{w}}$ (g mol <sup>-1</sup> )	NMR $M_{\text{n}}$ (g mol <sup>-1</sup> )	Hydrophilic : hydrophobic ratio
PECE	mPEG-PCL-mPEG	0	8	0	0.111	1.1	11 688	3220	1 : 2
P1	mPEG-PCL-PLA-PCL-mPEG	4	4	0.04	0.038	1.1	11 069	3230	1 : 2
P2	mPEG-PLA-PCL-PL-mPEG	4	4	0.04	0.038	1.1	13 240	3230	1 : 2
P3	mPEG-PCL-PLA-PCL-mPEG	1	7	0.014	0.07	1.2	13 014	3230	1 : 2
P4	mPEG-PLA-PCL-PLA-mPEG	1	7	0.014	0.07	1.2	15 492	3230	1 : 2
P5	mPEG-PCL-PLA-PCL-mPEG	6	1	0.055	0.018	1.1	12 896	3240	1 : 2
P6	mPEG-PLA-PCL-PLA-mPEG	6	1	0.055	0.018	1.3	21 459	3120	1 : 2



ogenous colloidal suspension was formed. Briefly, 300 mg of each polymer was mixed with 700  $\mu\text{L}$  of deionised water (42.8% w/v) and vortexed for 5 minutes. The mixture was subjected to repeated cycles of ice-cooling followed by incubation at 50  $^{\circ}\text{C}$  for 5 minutes each until a clear and homogeneous colloidal suspension was obtained. The suspension was then diluted to a final concentration of 30% w/v using deionised water. Finally, the hydrogels were sterilised by filtration through a 0.22  $\mu\text{m}$  membrane filter and stored at 4  $^{\circ}\text{C}$  until further use.

**Dynamic rheological study assessment of hydrogels.** The rheological properties of blank hydrogels (30% w/v) were investigated using an Anton Paar MCR 302 Modular Compact Rheometer (Austria). Samples were placed between parallel plates (25 mm diameter, 1 mm gap) and subjected to a temperature ramp from 10 to 60  $^{\circ}\text{C}$  at a heating rate of 1  $^{\circ}\text{C min}^{-1}$ . The storage modulus ( $G'$ ) and loss modulus ( $G''$ ) were measured under controlled strain (1%) and frequency (1.0 Hz). The gelation temperature ( $T_{\text{gel}}$ ) was defined as the point at which  $G'$  surpassed  $G''$ . All rheological data were analysed using the instruments RheoCompass software. The optimal pentablock polymer (P2), demonstrating a sol state below 20  $^{\circ}\text{C}$  and transitioning to a relatively rigid hydrogel between 35–40  $^{\circ}\text{C}$ , was selected for further characterisation and will be referred to as PELCLE hereafter.

#### Physicochemical characterisation and comparison of PECE and PELCLE hydrogels

**Dynamic light scattering (DLS).** PECE and PELCLE micelles (1% w/w) were prepared by dispersing the respective polymers in deionised water (1 mL) and vortexing for 5 minutes to facilitate dissolution. The solutions were then subjected to temperature cycling, alternating between ice-cooling followed by incubation at 50  $^{\circ}\text{C}$  for 5 minutes each until clear and transparent. The hydrodynamic diameter ( $Z$ -avg) of the resulting nanoparticles was measured at various temperatures using a Zetasizer NanoZS (Malvern Instruments, UK).

**Transmission electron microscopy (TEM).** To visualize the physical crosslinking and aggregation of PECE and PELCLE nanoparticles (NPs), transmission electron microscopy (TEM) analysis was performed on freshly prepared particles that were previously maintained at 20  $^{\circ}\text{C}$  and 37  $^{\circ}\text{C}$  for 2 h. NP suspensions (1% w/w in deionised water) were equilibrated at the respective temperatures for 30 minutes. Subsequently, 10  $\mu\text{L}$  aliquots were deposited onto glow-discharged formvar/carbon-coated TEM grids and allowed to adsorb for 10 minutes. Excess solution was removed, followed by negative staining with 2% (w/v) uranyl acetate for 1 minute. After air-drying, the grids were imaged using a Tecnai Biotwin TEM at an accelerating voltage of 100 kV.

**Scanning electron microscopy (SEM).** Blank hydrogels were snap-frozen in liquid nitrogen and lyophilised. The resulting dried samples were mounted on aluminium stubs using double-sided carbon tape and sputter-coated with an 8 nm layer of iridium (Model: 150 T ES, Quorum, UK). Morphological analysis was performed using a JEOL 7100F

scanning electron microscope (JEOL, UK) operating at an accelerating voltage of 15 kV.

**In vitro degradation and swelling ratio determination.** PECE and PELCLE hydrogels (100  $\mu\text{L}$ , 30% w/v) were prepared in pre-weighed 2 mL Eppendorf tubes and allowed to gel at 37  $^{\circ}\text{C}$  for 30 minutes. The initial weight ( $W_0$ ) of each gel was recorded. Phosphate-buffered saline (PBS, pH 7.4) was added to each tube, and the hydrogels were incubated at 37  $^{\circ}\text{C}$  for one week. After incubation, the PBS was removed, and the gel weight ( $W_s$ ) was measured. This process was repeated at pre-determined intervals over 90 days. At the study's conclusion, the final hydrogel weight was recorded, and the samples were lyophilised for subsequent gel permeation chromatography (GPC) analysis to assess polymer degradation.

The swelling ratio (%) of the hydrogels was calculated using the following equation:

$$\% \text{ Swelling} = \left( \frac{W_s - W_0}{W_0} \right) \times 100$$

**In vitro injectability, gelation, and hydrophilic drug retention.** The injectability, gelation kinetics, and immediate hydrophilic drug retention of PECE and PELCLE hydrogels (30% w/v) were evaluated qualitatively. Cyanine5.5.alkyne (Cy5.5, 10  $\mu\text{g}$ ) was incorporated into each hydrogel (1 mL) and loaded into a 1 mL syringe. Using a 29-gauge needle, the hydrogels were injected dropwise into preheated deionised water (25 mL, 37  $^{\circ}\text{C}$ ). Injectability was assessed by the absence of flow resistance, while gelation was considered rapid if hydrogel formation occurred immediately upon contact with the warm water. Immediate drug retention was evaluated by visually observing the Cy5.5 distribution within the hydrogel post-injection.

**In vitro drug release study.** To investigate the influence of PLA incorporation on drug release kinetics, various anti-cancer agents were loaded into PECE and PELCLE hydrogels (30% w/v). Gemcitabine (GEM, 25  $\mu\text{g mL}^{-1}$ ), oxaliplatin (OXA, 50  $\mu\text{g mL}^{-1}$ ), doxorubicin (DOX, 24  $\mu\text{g mL}^{-1}$ ), and olaparib (OLA, 50  $\mu\text{g mL}^{-1}$ ) were selected as representative drugs.

Drug-loaded hydrogels (100  $\mu\text{L}$ ) were injected into Eppendorf tubes and allowed to gel at 37  $^{\circ}\text{C}$  for 30 minutes. Pre-warmed PBS (pH 7.4, 1 mL) was added, and the tubes were incubated at 37  $^{\circ}\text{C}$ . At predetermined time points, the release medium was collected and replaced with fresh PBS. Drug concentrations were quantified using appropriate techniques.

For OXA and GEM, the same high performance liquid chromatography (HPLC) technique was utilised using a Shimadzu UFLC system (Shimadzu Corporation, Kyoto, Japan). A Hichrom 5 C18 (250  $\times$  4.6 mm) column at room temperature was used and the mobile phase consisted of water : acetonitrile (97 : 3) at a flow rate of 0.8  $\text{mL min}^{-1}$ . The injection volume was 40  $\mu\text{L}$  and the drug was monitored at 254 nm for both agents. The retention times of OXA and GEM were found to be 8.5 and 11 min, respectively. The method produced linear responses in the concentration range of 1–2500  $\mu\text{g mL}^{-1}$  for GEM and 1–250  $\mu\text{g mL}^{-1}$  for OXA.



The drug release samples of OLA were also analysed using HPLC quantification method (Agilent technologies, USA). A Hichrom 5 C18 column at room temperature (250 × 4.6 mm) was used and the mobile phase consisted of acetonitrile : ammonium acetate (10 mM, pH 4) (45 : 55) at a flow rate of 1.0 mL min<sup>-1</sup>. The injection volume was 20 µL and the drug was monitored at 254 nm. The retention time for OLA was found to be at 3.8 min. LC solution software was used to analyse the chromatograms. The method produced linear responses in the concentration range of 0.05–50 µg mL<sup>-1</sup>.

A fluorescence spectrophotometric method (TECAN Spark 10 M Multimode Microplate Reader (TECAN, Männedorf, Switzerland)) was used to assess the amounts of released DOX at an excitation/emission of 470/595 nm. The method produced linear responses in the concentration range of 0.01–5 µg mL<sup>-1</sup>.

The drug release mechanism for the initial 60% release was evaluated by fitting the data to zero-order, first-order, Hixson-Crowell (HC), Higuchi, and Korsmeyer-Peppas models. All mathematical equations are described in the ESI.†

### Evaluation of gemcitabine and oxaliplatin (GEMOX)-loaded PELCLE hydrogels for pancreatic cancer treatment in a model system

**Preparation, rheological characterisation, and *in vitro* release of GEMOX/PELCLE hydrogel (PELCLE-GEMOX).** PELCLE-GEMOX hydrogels were prepared by adding either 300 µL deionised water (DI) or solutions containing GEM and OXA in 300 µL DI water to PELCLE polymer, achieving a final concentration of 50 mg mL<sup>-1</sup> GEM, 5 mg mL<sup>-1</sup> OXA, and 30% w/v PELCLE. All samples were sterilised by filtration through a 0.22 µm membrane filter and stored at 4 °C until use. The rheological properties of blank PELCLE hydrogels (30% w/v) and PELCLE-GEMOX were assessed using an Anton Paar MCR 302 Modular Compact Rheometer, as described above. *In vitro* drug release kinetics from PELCLE-GEMOX were evaluated as described above. The presence of both GEM and OXA did not affect the individual peak areas or retention times in the HPLC analysis.

#### *In vitro* cell studies

**Cell culture.** Human pancreatic ductal adenocarcinoma PANC-FLuc cells were cultured in high-glucose Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) and 2 mM L-glutamine. Cells were maintained at 37 °C in a humidified atmosphere containing 5% CO<sub>2</sub>. To ensure stable firefly luciferase (FLuc) expression, PANC-FLuc cells were cultured in the presence of 1 µg mL<sup>-1</sup> puromycin every 5 passages.

**Assessment of *in vitro* metabolic activity and synergistic effects of drug combinations.** The cytotoxic effects of GEM, OXA, and GEMOX on PANC-FLuc cells were assessed using a PrestoBlue assay. Briefly, cells were seeded in 96-well plates (1.2 × 10<sup>4</sup> cells per well) and incubated for 24 hours. The medium was replaced with fresh medium containing GEM, OXA, or GEMOX at various molar ratios (GEM : OXA = 6.5 : 1, 13 : 1, 26 : 1) and concentrations. After 72 hours of exposure, the medium was

replaced with 10% PrestoBlue™ HS Cell Viability Reagent in DMEM, and fluorescence intensity (Ex/Em = 544/590 nm) was measured using a FLUOstar Omega plate reader (BMG LABTECH, UK). Relative metabolic activity was calculated, normalizing the negative control to 100%. Experiments were performed in triplicate, and results are presented as mean ± SD.

To evaluate the synergistic cytotoxicity of GEM and OXA on PANC-FLuc cells, the combination index (CI) analysis was utilised using the equation:<sup>29</sup>

$$CI = \frac{D_{\text{GEM-COMBO}}}{D_{\text{GEM-MONO}}} + \frac{D_{\text{OXA-COMBO}}}{D_{\text{OXA-MONO}}}$$

where  $D_{\text{GEM-MONO}}$  and  $D_{\text{OXA-MONO}}$  are the concentrations of GEM and OXA, respectively, required to achieve a specific metabolic activity effect level when administered alone, and  $D_{\text{GEM-COMBO}}$  and  $D_{\text{OXA-COMBO}}$  are the respective concentrations in the GEMOX combination needed for the same effect. A CI value below 1 indicates synergism, while a value equal to or above 1 suggests an additive or antagonistic effect.

***In vitro* metabolic activity of blank and GEMOX-loaded hydrogels.** The biocompatibility of blank P2 hydrogels was assessed using a direct contact method. PANC-FLuc cells were seeded in 96-well plates (1.2 × 10<sup>4</sup> cells per well) and incubated for 24 hours. P2 hydrogels were prepared as described previously and diluted with cell culture media (DMEM) to create a range of concentrations for testing. Specifically, 86.6 µL of the hydrogel in its sol state was diluted with 913.4 µL of DMEM to form a 2 mg mL<sup>-1</sup> P2 solution. Serial dilutions were then performed to achieve final hydrogel concentrations of 0.125 mg mL<sup>-1</sup>. These diluted hydrogel solutions were then added to the wells containing the cells. After 72 hours of exposure, the medium was replaced with 10% PrestoBlue™ HS Cell Viability Reagent in DMEM, and fluorescence intensity (Ex/Em = 544/590 nm) was measured after 20 minutes using a FLUOstar Omega plate reader. Relative metabolic activity was calculated, with the negative control normalised to 100%. Experiments were performed in triplicate, and results are presented as mean ± SD.

To evaluate the cytotoxicity of GEMOX-loaded PELCLE hydrogels, PANC-FLuc cells were seeded in 24-well plates (7.0 × 10<sup>4</sup> cells per well) and incubated for 24 hours. Free GEMOX solution (50 µL of DI water containing 2.5 mg GEM and 0.25 mg OXA, molar ratio of 13 : 1, respectively) or GEMOX-loaded PELCLE hydrogels (50 µL containing 30% w/v of hydrogel loaded with 2.5 mg GEM and 0.25 mg OXA, molar ratio of 13 : 1, respectively) were added to Greiner Transwell inserts (0.4 µm pore size) and pre-set at 37 °C for 30 minutes before being placed onto the cell-containing wells. Blank hydrogels and cell culture-grade water served as controls. After 72 hours of incubation, the inserts were removed, and cell viability was assessed using the PrestoBlue assay as described above. Experiments were performed in triplicate, and results are presented as mean ± SD.

#### *In vivo* tumour model studies

**Establishing subcutaneous *in vivo* PANC-FLuc models.** All animal experiments were conducted in accordance with UK Home Office Project Licence numbers PPL P435A9CF8 and



PP5089113, and with the approval of the University of Nottingham Animal Welfare and Ethical Review Body (AWERB). Experimental procedures adhered to the NCRI Guidelines on Experimental Neoplasia, the BVA/FRAME/RSPCA/UFWA Refining Procedures for the Administration of Substances Working Group report, and the NC3Rs Guidance for *in vivo* techniques, as well as the ARRIVE reporting guidelines.

Forty-two CD-1 NuNu mice (5–7 weeks old, 21 males, 21 females) were obtained from Charles River UK. Animals were housed in groups of three within individually ventilated cages, under a 12-hour light–dark cycle in a controlled environment ( $21 \pm 2$  °C,  $55\% \pm 10\%$  humidity). Food and water were provided *ad libitum*, and animal welfare was monitored throughout the study.

Following a one-week acclimatisation period, pancreatic tumours were initiated by subcutaneous injection of 100  $\mu\text{L}$  of  $1 \times 10^7$  mycoplasma-free PANC-FLuc cells suspended in Matrigel into the left flank. Tumour growth was monitored weekly *via* caliper measurements and bioluminescent imaging using the IVIS® Spectrum system. Animals were anaesthetised with a ketamine/medetomidine cocktail ( $75 \text{ mg kg}^{-1} + 1 \text{ mg kg}^{-1}$ , s.c.) prior to imaging and reversed with atipamezole ( $1 \text{ mg kg}^{-1}$ , s.c.) post imaging.

**Biodistribution and peritumoural retention of Cy5.5/PELCLE hydrogels.** To evaluate the peritumoural distribution and sustained release of drug-loaded PELCLE hydrogels, the hydrophilic fluorescent dye Cy5.5 was employed as a model drug. Established pancreatic cancer xenograft models (PANC-FLuc) were utilised. After 4 weeks of tumour growth, 12 mice were randomly divided into two groups ( $n = 6$  per group, 3 males, 3 females). One group received intratumoural injections of 50  $\mu\text{L}$  Cy5.5 solution ( $1 \mu\text{g mL}^{-1}$ ) in cell-culture grade water, while the other received 50  $\mu\text{L}$  Cy5.5-loaded PELCLE hydrogel ( $1 \mu\text{g mL}^{-1}$  Cy5.5, 30% w/v PELCLE). At predetermined time points (4, 24, 72, 192, 264, and 336 hours post-administration), mice were anaesthetised and imaged using the IVIS® Spectrum system (excitation/emission = 675/694 nm) to track Cy5.5 fluorescence. At each time point, one mouse from each group was euthanised, and tumours were excised for *ex vivo* imaging.

***In vivo* cytotoxicity of different treatment groups.** Following four weeks of tumour establishment, 30 mice were randomised into five groups ( $n = 6$  per group, 3 males, 3 females) and received peritumoural injections of 50  $\mu\text{L}$  of either: normal saline, blank PELCLE hydrogel, free GEMOX (intravenously), free GEMOX (peritumourally), or GEMOX-loaded PELCLE hydrogel (peritumourally). All GEMOX formulations were administered at a concentration of  $83.3 \text{ mg kg}^{-1}$  GEM and  $8.3 \text{ mg kg}^{-1}$  OXA.

Animals were monitored daily for clinical signs and weighed twice weekly for 28 days post-treatment to assess the biocompatibility of the formulations. Tumour growth was also monitored as described above. At the study's conclusion, mice were euthanised, and tumours were excised for *ex vivo* imaging, weighing, and fixation in neutral buffered formalin for further analysis.

**Histology, immunohistochemistry analysis of Ki-67 and TUNEL.** Fixed tumour and organ samples were dehydrated and embedded in paraffin using a Leica TP1020 tissue processor. Sections (10  $\mu\text{m}$ ) were cut on a Leica RM2245 microtome.

For haematoxylin and eosin (H&E) staining, slides were deparaffinised in xylene, rehydrated through a graded series of industrial methylated spirit (IMS) solutions, and stained with Harris haematoxylin and eosin. Stained sections were dehydrated, mounted with DPX mounting medium, and imaged using a NanoZoomer®-SQ (Hamamatsu).

Ki67 immunohistochemistry (IHC) was performed according to the manufacturer's instructions. Briefly, deparaffinised and rehydrated slides underwent antigen retrieval in sodium citrate buffer (pH 6.0) using a microwave. Following incubation with normal goat serum (NGS) and hydrogen peroxide, a peroxidase blocking solution was applied. Slides were then incubated with the primary antibody (Ki67, 1:50 dilution in 30% NGS) overnight at 4 °C, followed by the secondary antibody and DAB solution. After counterstaining with haematoxylin, slides were dehydrated, mounted, and imaged. Positive Ki67 staining was quantified using QuPath-0.4.3.

Apoptosis was assessed using a modified TUNEL assay with an antidigoxigenin-peroxidase system. Deparaffinised and rehydrated slides were permeabilised with proteinase K, and endogenous peroxidases were quenched with  $\text{H}_2\text{O}_2$ . Following incubation with the TUNEL labelling mixture, slides were counterstained with methyl green, dehydrated, mounted, and imaged. TUNEL-positive cells were quantified using QuPath-0.4.3.

### Statistical analyses

Statistical analyses of experimental data were conducted using *t*-test or analysis of variance (two-way ANOVA with Tukey's post-analysis test, with a single pooled variance). Values of  $p < 0.05$  were considered statistically significant. (\*\*\*\* $p < 0.0001$ , \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , and \* $p < 0.05$ ).

## Results and discussion

### Polymer synthesis, hydrogel formation, and rheological characterisation

A series of pentablock copolymers, including mPEG-*b*-PLA-*b*-PCL-HMDI-PCL-*b*-PLA-mPEG and mPEG-*b*-PCL-*b*-PLA-HMDI-PLA-*b*-PCL-mPEG, were synthesised *via* ring-opening copolymerisation, employing varying ratios of poly( $\epsilon$ -caprolactone) (PCL) to poly( $\text{D,L}$ -lactide) (PLA) as detailed in Table 1. Methoxypoly(ethylene glycol)-poly( $\epsilon$ -caprolactone)-methoxypoly(ethylene glycol) (mPEG-PCL-mPEG, or PECE), synthesised as previously reported<sup>21,22</sup> (Scheme 1A), served as a control to evaluate the impact of PLA incorporation on the dynamic rheology of the final product.

The copolymers were synthesised using mPEG<sub>500</sub> as a macroinitiator and Sn(Oct)<sub>2</sub> as a catalyst. Sequential addition of  $\text{D,L}$ -lactide or  $\epsilon$ -caprolactone followed by coupling with HMDI yielded the pentablock structures (Scheme 1B and C).





**Scheme 1** Polymer synthesis. Schematic representation of the synthetic procedures followed to prepare: (A) PECE triblock co-polymer; (B) mPEG-*b*-PLA-*b*-PCL-HMDI-PCL-*b*-PLA-mPEG pentablock co-polymer (PECLCE); and (C) mPEG-*b*-PCL-*b*-PLA-HMDI-PLA-*b*-PCL-mPEG pentablock co-polymer (PECLCE).

The successful synthesis and coupling were confirmed by  $^1\text{H}$  NMR, GPC, and FT-IR analyses. The average molar masses ( $M_{\text{wt}}$ ) of the prepared copolymers (PECE and P1–P6) were approximately  $3200 \text{ g mol}^{-1}$ , with a hydrophilic : hydrophobic ratio of 1 : 2. This was calculated from the  $^1\text{H}$ -NMR spectra (Fig. S1–S7 $^\dagger$ ), based on the peaks at 3.38 ppm (A,A':  $\text{CH}_3$  of mPEG), 2.3 ppm (J,J':  $\text{CH}_2$  of  $\epsilon\text{CL}$ ), and 5.10 ppm (K,K':  $\text{CH}$  of  $\text{D,L-LA}$ ), and the known  $M_n$  of mPEG ( $500 \text{ g mol}^{-1}$ ). GPC analysis showed the expected 2-fold increase in molar mass after HMDI addition, suggesting success of the coupling reaction (Fig. S8 $^\dagger$ ). All polymers exhibited a unimodal molecular weight distribution with polydispersity indices ( $D < 1.4$ ) (Table 1), however,  $M_w$  and  $M_w$  values from GPC were higher than those from NMR, which we attribute to the different solution conformations of these amphiphilic polymers in DMF compared to the PMMA standards. FT-IR analysis further validated the successful synthesis (Fig. S9 $^\dagger$ ). A strong  $\text{C}=\text{O}$  stretching band at  $1750 \text{ cm}^{-1}$  indicated the presence of ester bonds, while the disappearance of  $-\text{NCO}$  absorption peaks ( $2250\text{--}2270 \text{ cm}^{-1}$ ) and the appearance of  $\text{N-H}$  bending vibrations at  $1550 \text{ cm}^{-1}$  confirmed the completion of the urethane coupling reaction. The incorporation of a short urethane block into the polymer back-

bone was expected to enhance mechanical properties and impart self-healing properties owing to the dynamic nature of the  $\text{N-C}=\text{O}$  bond and the reversible hydrogen bonding interactions across carbamate linkages. $^{30\text{--}32}$

The thermoresponsive behaviour of all synthesised hydrogels (30% w/v) was initially assessed using the tube inversion method (Fig. 1A). At  $20^\circ\text{C}$ , all polymers, except P1, exhibited a free-flowing sol state. Upon heating to  $37^\circ\text{C}$ , PECE and P2 underwent a sol-gel transition, while P3–P6 remained viscous liquids.

Dynamic rheological measurements provided further insights into the gelation process, specifically by assessing their storage ( $G'$ ) and loss ( $G''$ ) moduli. At temperatures below  $20^\circ\text{C}$ , all polymers except P1 displayed low  $G'$  and  $G''$  values ( $<1 \text{ Pa}$ ), indicating good injectability due to their predominantly liquid-like behaviour. Upon heating, distinct differences in gelation behaviour emerged. PECE exhibited a gelation temperature ( $T_{\text{gel}}$ ) of  $21^\circ\text{C}$ , marked by the crossover of  $G'$  surpassing  $G''$ , and showed a substantial increase in both moduli at  $37^\circ\text{C}$ , indicative of a relatively stiff hydrogel (Fig. 1B). In contrast, P1, with  $G'$  consistently exceeding  $G''$ , exhibited a predominantly solid-like behaviour throughout the temperature range, suggesting poor injectability. P2 demonstrated a  $T_{\text{gel}}$  at





**Fig. 1** Thermoresponsive behaviour and rheological properties of polymeric materials. (A) Tube inversion test as a proxy for rheological behaviour of the thermoresponsive polymers (30% w/v) at 20 °C and 37 °C. (B) Temperature-dependent changes in storage modulus ( $G'$ ) and loss modulus ( $G''$ ) for polymeric materials (30% w/v), illustrating their rheological behaviour during the gelation process. ( $T_{gel}$  = gelation temperature, NA: not applicable).

29 °C, implying a wider injection window compared to PECE. Furthermore, at 37 °C, P2 formed a softer hydrogel compared to PECE, as evidenced by its lower storage modulus ( $G'$ ). It is important to note that only PECE and P2 exhibited a clear sol-gel transition state where  $G'$  consistently exceeded  $G''$  upon heating.

On the other hand, P3 and P4 displayed similar gelation behaviour, with  $T_{gel}$  at 34 °C. P5 exhibited an atypical pattern, with  $G'$  briefly exceeding  $G''$  at 31 °C before  $G''$  dominated again. P6, with  $G''$  consistently higher than  $G'$ , remained a viscous liquid throughout the tested temperature range

(Fig. 1B). This observation highlights that P3–P6 do not behave as classical hydrogels, but rather exhibit complex temperature-dependent viscoelastic behaviour.

These rheological observations, along with the observed macroscopic gelation behaviour, suggest that both block orientation and the PLA-PCL ratio significantly influence the gelation and mechanical properties of the resulting hydrogels. While no clear trend correlating block properties and gelation behaviour was discernible, likely due to the inherent disorder associated with PLA and the use of D,L-lactide,<sup>33,34</sup> a consistent finding was the decrease in hydrogel stiffness upon PLA incor-



poration into the PECE backbone. This reduction in stiffness is attributed to the contrasting structural characteristics of PLA and PCL. The low crystallinity and quasi-amorphous nature of PLA, arising from the random incorporation of D,L-lactide, contribute to enhanced chain flexibility and reduced rigidity in PLA-containing hydrogels.<sup>28,35</sup> In contrast, PECE hydrogels, lacking the PLA component, exhibit a more ordered and tightly packed crystalline structure due to their PCL segments, resulting in increased resistance to deformation and a stiffer hydrogel network.<sup>28,35</sup>

Based on our objective of developing an injectable hydrogel that remains liquid below 20 °C and forms a stable gel at physiological temperature (35–40 °C), we selected PECE and P2 (PELCLE) as the candidate materials for further investigation.

### Influence of PLA incorporation on nanoparticle formation

The amphiphilic nature of PECE and P2 block copolymers suggested their potential for self-assembly into micellar-like

nanoparticles (NPs) in aqueous solutions.<sup>36</sup> To investigate the impact of PLA incorporation on NP formation, we employed dynamic light scattering (DLS) and transmission electron microscopy (TEM). DLS analysis of 1% w/w aqueous solutions prepared using the temperature cycling approach revealed that both PECE and P2 (PELCLE) formed NPs at room temperature, with average sizes of ~76 and 25 nm, respectively. Upon heating to 37 °C, both NP types exhibited increased aggregation and size, reaching ~150 nm for PECE and ~75 nm for P2 (Fig. 2A and B). Interestingly, P2 NPs were consistently smaller than PECE NPs across all tested temperatures (Fig. 2C).

TEM imaging supported these findings, revealing spherical morphologies for both polymers at 20 °C (Fig. 2D and E). However, some aggregation was observed, being less pronounced in P2 micelles. TEM analysis showed that P2 micelles had a smaller average particle size (mean = 12.5 nm), and a narrower size distribution (PDI = 0.112) compared to PECE (mean = 16.5 nm, PDI = 0.239). At 37 °C, aggregation increased for both polymers, consistent with the DLS results.



**Fig. 2** Characterisation of thermo-responsive PECE and P2 NPs. Size distribution analysis of 1% (w/w) of (A) PECE (20 °C: Z-avg = 75.7 nm, PDI = 0.221; 37 °C: Z-avg = 152.9 nm, PDI = 0.296) and (B) P2 NPs (20 °C: Z-avg = 24.9 nm, PDI = 0.207; 37 °C: Z-avg = 73.7 nm, PDI = 0.043). (C) Z-avg (nm) differences between PECE and P2 NPs at different temperatures. Transmission electron microscopy (TEM) imaging and TEM size distribution analysis of (D) PECE and (E) P2 NPs at 20 °C (PECE: mean = 16.5 nm, PDI = 0.239; P2: mean = 12.5 nm, PDI = 0.112) and 37 °C (scale bar = 200 nm).



The observed temperature-induced aggregation of PECE and P2 micelles is consistent with their inherent thermo-responsive sol-gel transition. As reported for similar amphiphilic copolymers, micellar properties are often governed by interactions within their hydrophobic core.<sup>36</sup> Elevated temperatures weaken polymer-water interactions, promoting chain collapse, aggregation, and the formation of physical crosslinks that culminate in a hydrogel network.<sup>37,38</sup> This suggests that the temperature sensitivity and propensity for physical cross-linking inherent to PECE and P2 micelles drive their gelation upon heating. This size difference is likely due to the PLA block, which has been shown to enhance chain packing within the hydrophobic core through alkyl chain-chain interactions.<sup>39</sup> This observation suggested in turn that micellar size might influence the macroscopic mechanical properties of the resulting hydrogels. Smaller micelles, as seen in P2, were expected to alter chain entanglement and cross-linking density within the hydrogel network, potentially impacting its stiffness, elasticity, and overall mechanical performance.

### PLA incorporation impacts PECE hydrogel degradation and swelling

To investigate further the influence of PLA incorporation on hydrogel properties, we evaluated the degradation and swelling behaviour of PECE and P2 hydrogels at 37 °C in PBS pH 7.4. Visual observation revealed that PECE hydrogels maintained their volume over 90 days (Fig. 3A), while P2 hydrogels exhibited a noticeable decrease (Fig. 3B). However, measurements of polymer mass after 90 days showed an increase for PECE hydrogels (from 104.7 ± 7.6 mg to 174.8 ± 8.6 mg) and a decrease for P2 hydrogels (from 104.2 ± 7.5 mg to 70.3 ± 6.3 mg). The increase in PECE mass suggests swelling, which could mask degradation if assessed by mass alone. Therefore, Gel Permeation Chromatography (GPC) was employed to assess degradation in both hydrogels. GPC analysis revealed a shift to lower molecular weights for both PECE and P2, confirming degradation. Specifically, PECE exhibited a 1.7-fold decrease in molecular weight over 90 days, changing from ~11.7 kg mol<sup>-1</sup> to 7.3 kg mol<sup>-1</sup>. P2 underwent a more substantial reduction, with a 3.2-fold decrease from 13.2 kg mol<sup>-1</sup> to 4.3 kg mol<sup>-1</sup> over the same period (Fig. 3C and D). The accelerated degradation of P2 is attributable to the inherent higher hydrolytic degradation of PLA, which is known to degrade faster than PCL.<sup>27</sup>

In terms of swelling behaviour, PECE hydrogels demonstrated a significant mass increase of 73 ± 6% within the first 7 days ( $p < 0.0001$ ), highlighting their acute high water absorption capacity. No further significant change in hydrogel mass was seen in the remainder study period ( $p > 0.05$ ) (Fig. 3E). Conversely, P2 hydrogels exhibited non-significant increase in mass ( $p$ -value = 0.452) during the first 7 days, potentially due to the PLA blocks, which can decrease hydrogel swelling ratio through increased cross-link density and reduced viscoelastic restoring forces.<sup>40</sup> Instead, P2 showed a gradual mass loss, reaching a significant reduction of 30 ± 6% by 90 days ( $p < 0.0001$ ) further emphasizing its propensity for degradation rather than swelling (Fig. 3E).<sup>27</sup>

### *In vitro* assessment of injectability, gelation, drug retention, drug release


To evaluate injectability, gelation kinetics, and immediate hydrophilic drug retention of the materials, PECE and P2 solutions (30% w/v) were loaded with Cyanine5.5.alkyne (Cy5.5, 10 µg mL<sup>-1</sup>) and injected through a 29-gauge needle at room temperature (Videos 1A and B, ESI†). The materials were then injected dropwise into pre-heated deionised water (37 °C, 25 mL). The solutions were easy to inject and gelled rapidly upon contact with the warm water, with Cy5.5 clearly entrapped within the formed hydrogel network (Videos 1A and B, ESI†). Subsequent cooling of the hydrogels on ice resulted in complete dissolution and release of the dye into the surrounding solution (Fig. S10A and B†), demonstrating the reversibility of the sol-gel transition. This experiment provides a visual assessment of the immediate behaviour of the hydrogels upon injection at physiological temperature.

Following the initial characterisation, various anti-cancer agents with diverse cLogP values were loaded into PECE and P2 hydrogels at comparable concentrations to assess their *in vitro* release profiles over a 2-week period (Fig. 3F). The release data, up to a maximum of 60%, or the total amount released within the experimental timeframe if less than 60%, were tested for fit to zero-order, first-order, Hixson-Crowell, Higuchi, and Korsmeyer-Peppas models to elucidate the release mechanisms and investigate any potential correlation between drug lipophilicity (cLogP) and release kinetics (Table 2).

For all therapeutic agents, the release profiles were best described by the Higuchi and/or Korsmeyer-Peppas (K-P) models as demonstrated by the  $R^2$  values in Table 2. The Higuchi model, commonly used for polymeric matrices, suggests that drug release is primarily governed by diffusion, assuming negligible swelling of the matrix.<sup>41,42</sup> The K-P model, an extension of the Higuchi model, is specifically tailored for drug release from swellable polymeric systems like hydrogels and is a valuable tool for discerning the contributions of diffusion and hydrogel swelling.<sup>43,44</sup> The exponent ' $n$ ' characterizes the release mechanism:  $n \leq 0.5$  indicates diffusion-controlled release,  $n = 1$  signifies swelling-controlled release,  $0.5 < n < 1$  suggests anomalous transport (a combination of diffusion and swelling), and  $n > 1$  implies polymer erosion or degradation.

We first examined the release of oxaliplatin (OXA, logP = -1.39). OXA exhibited a similar biphasic release profile from both hydrogels, with a burst release in the first 6 hours followed by a slower sustained release. Approximately 75 ± 0.5% and 73 ± 2% of the drug were released within the first 6 hours from PECE and P2, respectively (Fig. 3F). The release profiles were well-described by both the Higuchi and Korsmeyer-Peppas (K-P) models, suggesting a diffusion-controlled mechanism, which is consistent with the K-P model ' $n$ ' value of 0.3. Notably, P2 hydrogels exhibited a slightly slower release rate compared to PECE (Table 2). This difference may be attributed to the denser structure and reduced swelling of P2, hindering the diffusion of OXA through the hydrogel matrix.





**Fig. 3** Comparative characterisation of PECE and P2 hydrogels: degradation, swelling, and drug release. Visual observation changes of (A) PECE and (B) P2 hydrogel over 90 days. Changes in the molecular weight following 90 days incubation in PBS pH 7.4 for (C) PECE and (D) P2 hydrogel, assessed by GPC. (E) % weight change relative to initial weight of PECE and P2 hydrogels measured at predetermined times over 90 days period ( $n = 8$ ) (\*\*\*\* $p < 0.0001$ , \*\*\* $p < 0.001$ , \*\* $p < 0.01$ , and \* $p < 0.05$  ordinary one-way ANOVA with Tukey's post-analysis test). (F) *In vitro* drug release studies conducted in PBS at pH 7.4, showcasing diverse agents employed in cancer treatments for both PECE and P2 hydrogels.



**Table 2** Mathematical model fitting for the initial 60% of drug release across various therapeutic agents

	cLogP	Zero		First		Hixson		Higuchi		K-P		
		$R^2$	$K$	$R^2$	$K$	$R^2$	$K$	$R^2$	$K$	$R^2$	$K$	$n$
OXA-PECE	-1.39	0.99	10.4	0.97	0.3	0.95	0.3	1.00	33.2	1.00	35.0	0.5
OXA-P2		0.99	10.7	0.98	0.2	0.97	0.3	1.00	31.3	1.00	30.6	0.5
GEM-PECE	-1.06	0.68	1.4	0.67	0.0	0.61	0.1	0.79	13.5	0.91	33.8	0.3
GEM-P2		0.87	1.7	0.85	0.0	0.79	0.1	0.91	13.5	0.98	26.2	0.3
DOX-PECE	0.317	0.80	0.0	0.75	0.0	0.74	0.0	0.93	0.6	0.97	1.6	0.3
DOX-P2		0.66	0.1	0.70	0.0	0.67	0.0	0.86	2.7	0.95	9.0	0.3
OLA-PECE	1.24	0.73	0.2	0.83	0.0	0.80	0.0	0.93	3.8	0.94	1.7	0.7
OLA-P2		0.91	0.1	0.94	0.0	0.93	0.0	0.99	2.7	0.99	1.6	0.6

Gemcitabine (GEM, cLogP = -1.06), another hydrophilic drug, also showed a slower and more sustained release from P2 compared to PECE, particularly in the initial 6 hours ( $50 \pm 0.5\%$  vs.  $60 \pm 1.5\%$  release, respectively). The K-P model confirmed diffusion-controlled release ( $n = 0.3$  for both), with P2 demonstrating a slower rate ( $K = 26.2$ ) than PECE ( $K = 33.8$ ) (Fig. 3F).

In contrast, the release of doxorubicin hydrochloride (DOX.HCl, cLogP = 0.317) was slower from PECE than P2 ( $40 \pm 2\%$  vs.  $7 \pm 1\%$  release in 72 hours) (Fig. 3F). The K-P model again suggested diffusion-controlled release ( $n = 0.3$  for both), but with PECE exhibiting a slower rate ( $K = 1.6$ ) than P2 ( $K = 9.0$ ). These data might be partly explained *via* specific interactions between the charged pendant aminoglycoside ring of DOX with lactate and caproic acid terminated fragments resulting from polymer degradation. The more rapid degradation of the poly(lactic acid) regions in P2 compared to the poly(caprolactone)-only polymer PECE would lead to more rapid formation of carboxyl end-groups, potentially trapping DOX *via* electrostatic interactions.

The hydrophobic drug olaparib (OLA, cLogP = 1.24) exhibited a slower and more sustained release profile from P2 compared to PECE (Fig. 3F). Within the first 72 hours, OLA release was  $23.0 \pm 3.3\%$  from P2 and  $43.3 \pm 0.7\%$  from PECE. The K-P model indicated anomalous transport for both formulations ( $n = 0.6$  for P2,  $n = 0.7$  for PECE), with P2 demonstrating a slower release rate ( $K = 1.6$  vs.  $1.7$  for PECE).

These findings reveal several key trends. First, increasing drug hydrophobicity (higher cLogP) generally correlates with decreased release percentage and rate for both hydrogels. This is likely due to the reduced water solubility and slower dissolution of more hydrophobic drugs.<sup>45</sup> Second, drug release mechanisms appear to be influenced by cLogP values, with more hydrophilic drugs following diffusion-controlled release and more hydrophobic drugs exhibiting anomalous transport. This aligns with previous reports.<sup>43</sup> Third, while P2 hydrogels generally exhibited slower release rates than PECE for most agents, the data for DOX.HCl highlighted the potential influence of specific polymer-drug interactions on release kinetics.

### Preclinical assessment of GEMOX-loaded P2 hydrogels for pancreatic cancer therapy

The thermoresponsive behaviour of P2 suggested it might be useful as an *in situ* gelling depot for drug delivery in the challenging conditions of pancreatic ductal adenocarcinoma

(PDAC).<sup>44</sup> The poor prognosis and limited treatment options for PDAC, in conjunction with the challenges associated with current chemotherapeutic regimens, highlight the urgent need for improved therapeutic strategies. The combination of injectability, hydrolytic degradation, controlled drug release, and minimal swelling might offer a means to overcome some of these obstacles, hence we investigated the use of P2 hydrogels as a delivery system for the combination therapy of gemcitabine and oxaliplatin in the context of PDAC treatment.

**Determination of clinically relevant GEMOX dose.** The combination of gemcitabine (GEM) and oxaliplatin (OXA), known as GEMOX, is a widely used therapeutic strategy in pancreatic cancer treatment, exploiting the distinct yet complementary mechanisms of action of each drug. To identify molar ratios appropriate to detect synergism in cell studies, which might not match exactly those used clinically, we assessed the metabolic activity of PANC1-FLuc cells following 72-hour exposure to various free GEM, free OXA, and GEMOX combinations. We selected three GEM : OXA molar ratios (6.5 : 1, 13 : 1, and 26 : 1) centered around the clinically relevant molar ratio of 13 : 1 (1000 mg m<sup>-2</sup> GEM, 100 mg m<sup>-2</sup> OXA).<sup>11,46</sup> Cytotoxicity was evaluated using the PrestoBlue assay. All treatments exhibited dose-dependent cytotoxicity, with GEMOX combinations consistently demonstrated lower IC<sub>50</sub> values compared to the free drugs (Fig. 4A). Specifically, GEMOX 6.5 : 1, 13 : 1, and 26 : 1 showed IC<sub>50</sub> values of 0.193  $\mu$ M, 0.213  $\mu$ M, and 0.280  $\mu$ M, respectively, compared to free GEM (IC<sub>50</sub> = 0.451  $\mu$ M) and free OXA (IC<sub>50</sub> = 9.994  $\mu$ M) highlighting the enhanced cytotoxic effect achieved when GEM and OXA are combined.

Combination index (CI) analysis at the IC<sub>50</sub> further confirmed the synergistic effect of GEMOX, with CI values below 1 (Fig. 4B). Considering the established GEMOX dosage regimen and the dose-limiting toxicity of OXA, we selected the clinically relevant 13 : 1 molar ratio for subsequent studies.<sup>11</sup>

**Impact of GEMOX loading on P2 hydrogel properties and *in vitro* cytotoxicity.** The sol-gel transition of blank P2 and GEMOX-loaded P2 hydrogels (30% w/v) was assessed using the tube inversion method (Fig. 4C). Incorporation of GEMOX (13 : 1 - GEM : OXA molar ratio) did not significantly affect the gelation properties, causing only a marginal increase in the apparent gelation temperature ( $T_{\text{gel}}$ ). The observed  $T_{\text{gel}}$  was 29.7 °C without drug loading and 30.0 °C with GEMOX loading (Fig. 4D), indicating no significant disruptions in the





**Fig. 4** *In vitro* evaluation of GEMOX-loaded P2 hydrogels. (A) Dose–response curves comparing the efficacy of free GEMOX treatments at various molar ratios to individual free GEM and free OXA treatments. (B) Combination index (CI) analysis demonstrating the synergistic activity of GEMOX at  $IC_{50}$ . (C) Tube inversion test visualising the sol–gel transition of P2-GEMOX hydrogels at 20 °C and 37 °C. (D) Temperature-dependent changes in storage modulus ( $G'$ ) and loss modulus ( $G''$ ) for P2-GEMOX hydrogels, illustrating their rheological behaviour. (E) *In vitro* drug release profiles of GEM (50 mg mL<sup>-1</sup>) and OXA (5 mg mL<sup>-1</sup>) from GEMOX-loaded P2 hydrogels in PBS at pH 6.8. (F) Metabolic activity of PANC-1 cells after direct contact with varying concentrations of P2 gels. (G) Comparative analysis of the effects of free GEMOX and GEMOX-P2 on PANC-FLuc cells over a 72-hour period, presented as mean  $\pm$  SD ( $n = 3$ ).



P2 network.<sup>47</sup> *In vitro* drug release studies in PBS (pH 6.8), mimicking the acidic tumour microenvironment,<sup>11</sup> showed sustained release of both GEM and OXA from P2-GEMOX HGs over an extended period (Fig. 4E). GEM release from GEMOX-loaded P2 was 78% in 72 hours while OXA release reached 21% at 72 hours.

To assess the cytotoxicity of the blank hydrogel, a direct contact assay was performed. Varying concentrations of the gel (125–2000  $\mu\text{g mL}^{-1}$ ) were applied to PANC-1 cells, and no reduction in metabolic activity was observed, confirming the lack of acute toxicity of the polymer (Fig. 4F). These results were further confirmed in Transwell® systems, where no significant difference ( $p > 0.05$ ) was found between P2 hydrogels loaded in Transwells® and negative controls. This suggests that the products of acute degradation of the polymer do not produce acute toxicity in cells. Similarly, no significant difference ( $p > 0.05$ ) was observed between GEMOX-P2 and free GEMOX loaded in Transwells® on PANC-FLuc cells, indicating that the hydrogel formulation does not hinder drug release and activity in this more biorelevant environment (Fig. 4G).

***In vivo* release kinetics and tumour retention.** To model *in vivo* drug release, we incorporated the water-soluble fluorescent dye Cy5.5 into P2 hydrogels and compared its release kinetics to that of a free Cy5.5 solution over a two-week period. Subcutaneous xenograft tumours were established, and following treatment, tumours were excised at various time points for *ex vivo* imaging to assess hydrogel localisation and Cy5.5 retention. Both Cy5.5/P2 and free Cy5.5 showed initial distribution around the tumour cells four hours post-injection (Fig. 5A). However, the intensity of fluorescence from the free Cy5.5 group diminished rapidly due to clearance into the circulation, whereas Cy5.5 fluorescence was detected at the tumour site in the Cy5.5/P2 group for up to 336 hours, indicating prolonged retention of the dye in the gel at the injection point.

*Ex vivo* imaging of excised tumours confirmed that the dye remained localised at the tumour site throughout the study period, indicating that the hydrogel was not degraded to fragments that could be cleared during this time (Fig. 5B). This enhanced tumour retention suggests that chemotherapeutic agents encapsulated within the hydrogel might persist within the tumour microenvironment for extended durations, potentially leading to a more prolonged therapeutic effect.

***In vivo* anti-tumour activity, immunohistochemistry, and systemic toxicity of treatments.** Encouraged by the promising *in vitro* results demonstrating sustained drug release, and synergistic GEMOX activity, we investigated the therapeutic potential of GEMOX-loaded P2 in a subcutaneous PANC-FLuc xenograft mouse model. Although xenografts cannot recapitulate the correct physiology, this model was chosen for the easier local administration of hydrogels and lower invasiveness compared to highly aggressive orthotopic pancreatic cancers. Treatment groups included GEMOX intravenous (IV, standard of care), GEMOX peritumoural, blank P2 peritumoural, and normal saline peritumoural (negative control). All GEMOX formulations were administered at a clinically relevant 13 : 1 molar ratio (83.3 mg kg<sup>-1</sup> GEM, 8.3 mg kg<sup>-1</sup> OXA).

Throughout the 28-day study period, no significant changes in body weight or behaviour were observed in any treatment group, suggesting good tolerability (Fig. S11A†). However, low and variable tumour growth was observed across all groups, including the negative controls (Fig. S11B†), hindering the assessment of tumour regression. While high variability in xenograft pancreatic tumour growth is not unprecedented,<sup>48</sup> we were not able in the time of study to ascertain why this occurred, and thus for ethical reasons were not able to repeat the experiments. Additionally, the subcutaneous model presented challenges in accurately measuring tumour volume due to the hydrogel adherence, leading to variability in tumour weight within different groups (Fig. S11C and D†).

We therefore focused on immunohistochemical analysis to evaluate the effects of different treatments on tumour and major organ tissues. H&E staining was used to assess changes in tissue architecture and cellular organisation.<sup>49</sup> No histological alterations were observed in major organs across all treatment groups, suggesting minimal systemic toxicity (Fig. S12†). In tumours treated with blank hydrogel, tissue morphology closely resembled that of the normal saline control, with intact cell structures (Fig. 5C). Both GEMOX IV and GEMOX PT treatments resulted in a slight loss of tissue integrity with occasional empty nuclei (Fig. 5C), indicative of limited therapeutic activity. In contrast, GEMOX-P2 treatment induced detectable changes, with evidence of nuclear shrinkage and loss of cell integrity (Fig. 5C). Subsequently, a TUNEL assay was employed to evaluate the extent of apoptosis within the tumour tissues under different treatment conditions (Fig. 5C). Consistent with the H&E staining, the TUNEL assay revealed a significantly higher number of apoptotic cells per  $\mu\text{m}^2$  in the GEMOX-P2 group compared to both GEMOX IV and PT groups (211.7  $\pm$  80.0 vs. 9.3  $\pm$  5.7 and 4.1  $\pm$  1.6, respectively;  $p = 0.0003$  and  $p = 0.0002$ , respectively) (Fig. 5D). Similarly, the KI-67 proliferation assay, which detects the expression of the KI-67 proliferation marker,<sup>50</sup> demonstrated a significantly lower number of proliferative cells per  $\mu\text{m}^2$  in the GEMOX-P2 group compared to GEMOX IV and PT (9.9  $\pm$  2.0 vs. 70.4  $\pm$  5.2 and 130.5  $\pm$  7.8, respectively;  $p = 0.0065$  and  $p < 0.0001$ , respectively) (Fig. 5E).

These immunohistochemical assessments collectively suggest that peritumoural injection of GEMOX-P2 hydrogel induced significantly greater apoptosis and inhibited cell proliferation in the tumour tissues more effectively than both intravenous and peritumoural GEMOX. This enhanced anti-tumour activity was achieved while maintaining minimal systemic toxicity, as evidenced by stable body weight throughout the study. At study termination, mice treated with GEMOX-P2 hydrogel had an average body weight of 29.6  $\pm$  2.6 g, a 1.03-fold increase from their pre-treatment baseline of 28.6  $\pm$  1.26 g. We suggest that the sustained drug release from the hydrogel likely contributed to this enhanced therapeutic effect, at least in the regions of the tumours in proximity to the gels, underscoring the potential of this approach as a treatment option for pancreatic cancer.

It is important also to note the limitations of the *in vivo* studies. Xenograft tumours do not replicate the physiological environment of pancreatic cancers but are often adopted





**Fig. 5** *In vivo* evaluation of P2 hydrogels in a pancreatic cancer model. (A) *In vivo* release study of Cy5.5 as a model hydrophilic drug from Cy5.5/P2 hydrogels compared to free Cy5.5 solution over a 2-week duration, shedding light on the sustained release properties of the hydrogel. (B) Visualisation of excised tumours demonstrating the retention of Cy5.5/hydrogel around the tumour over time. (C) Representative immunohistochemistry images depicting H&E, TUNEL, and KI-67 analyses (scale bar = 100  $\mu$ m). Arrows represent proliferation positive regions. (D) Quantification of the TUNEL assay illustrating results for various treatments. (E) Quantification of the KI-67 assay showcasing results for different treatments. (\*\*\*\* $p$  < 0.0001, \*\*\* $p$  < 0.001, \*\* $p$  < 0.01, and \* $p$  < 0.05 ordinary one-way ANOVA with Tukey's post-analysis test).



because the establishment of orthotopic pancreatic tumours in mice is complex experimentally and difficult ethically. Tumours grow rapidly in pancreatic sites in mice, leading to limited treatment windows and the need for unacceptably large numbers of animals in a study if survival in control arms is short. We chose a xenograft model to establish the safety of the gels and also to evaluate if local anti-tumour effects could be achieved. However, while these primary goals were achieved, this model did not allow a full efficacy study in terms of tumour regression because of highly variable tumour growth in the animals. In addition, we noted a sex-dependent component in both tumour size and in reduction following treatment, which warrants further investigation (Fig. S13†). A more extensive study now that we have established safety is under consideration, with a likely additional treatment component of an external stimulus, such as ultrasound, to disrupt the gel and pancreatic stromal matrix locally, ensuring site-specific release and optimal therapeutic window for the drug combinations.

## Conclusion

This study successfully demonstrated the incorporation of PLA blocks into PECE hydrogels, yielding PELCLE pentablock copolymers with tailored properties. Our primary objective was to investigate the impact of PLA incorporation on hydrogel characteristics, not to replace PECE, but to provide an alternative system with enhanced hydrolytic degradation, reduced swelling, and slower drug release profiles – attributes desirable for certain applications. The introduction of PLA maintained the thermoresponsive behaviour of PECE, allowing both polymers to self-assemble into micelles, as confirmed by DLS and TEM. Notably, PELCLE exhibited smaller micellar sizes compared to PECE, potentially influencing drug delivery and release. Rheological and mechanical analyses revealed that PELCLE hydrogels possessed lower storage modulus, complex viscosity, and stiffness, alongside increased deformability compared to PECE, attributable to the distinct characteristics of PLA blocks. Furthermore, PLA incorporation enhanced hydrolytic biodegradation and reduced swelling in PELCLE hydrogels.

Both PECE and PELCLE demonstrated desirable features such as injectability and rapid gelation at body temperature, effectively entrapping both hydrophilic and hydrophobic drugs. Drug release studies revealed that hydrophobicity and cLogP values influence release kinetics, with PELCLE generally exhibiting slower release compared to PECE.

To showcase the potential of PELCLE, we investigated its application in pancreatic cancer treatment using GEMOX as a model drug combination. *In vitro* studies demonstrated no acute toxicities of PELCLE gels, and *in vivo* experiments demonstrated sustained GEMOX release and enhanced injection site retention compared to free drug administration. Importantly, PELCLE hydrogels exhibited minimal systemic toxicity and drug-loaded P2 gels were shown to induce apopto-

sis in regions of tumour tissue to a higher extent than those of the free drugs injected by the same routes.

In conclusion, the pentablock PELCLE hydrogels represent a versatile platform for extended drug delivery, offering tuneable physicochemical properties and drug release profiles. Their potential extends beyond pancreatic cancer, suggesting broad applicability in various biomedical fields where localised and sustained drug delivery is desired.

## Author contributions

ElSherbeny Amr: conceptualisation, methodology, validation, formal analysis, investigation, visualisation, writing – original draft. Cara Moloney: methodology, investigation, supervision, writing – review & editing. Hulya Bayraktutan: investigation, visualisation, writing – review & editing. Nurcan Gumus: investigation, formal analysis, writing – review & editing. Andres Garcia Sampedro: investigation, visualisation, writing – review & editing. Oz Umut Can: investigation, supervision, writing – review & editing. Alison Ritchie: methodology, investigation, writing – review & editing. Shreeya Parmar: investigation. Marian Meakin: investigation. Ruman Rahman: supervision, writing – review & editing. Jennifer Ashworth: supervision, writing – review & editing. Anna Grabowska: supervision, writing – review & editing. Cameron Alexander: conceptualisation, supervision, writing – review& editing, funding acquisition, resources.

## Data availability

The data supporting this article have been included as part of the ESI† or are available from the corresponding authors Amr Elsherbeny and Cameron Alexander.

## Conflicts of interest

Jennifer C. Ashworth is a co-founder, shareholder and on the Scientific Advisory Board of Peptimatrix Limited.

## Acknowledgements

We thank UKRI/EPSCRC for funding [grants EP/R035563/1, EP/S021434/1, EP/V049291/1], the Little Princess Trust in partnership with CCLG and the Royal Society [Wolfson Research Merit Award WM150086 to CA]. UCO is thankful for a fellowship (2219) from the TUBITAK. We acknowledge Dr Patricia Monteiro for expert assistance in polymer synthesis and characterisation. This work was also supported *via* Anne McLaren fellowship funding from the University of Nottingham (JCA). We also thank Tom Hyde, Esme Ireson and Paul Cooling for expert technical support. The Nanoscale & Macroscale Research Centre (NMRC) is acknowledged for providing the facilities for TEM, SEM, and related analysis.



## References

- N. Bhattarai, J. Gunn and M. Zhang, Chitosan-based hydrogels for controlled, localized drug delivery, *Adv. Drug Delivery Rev.*, 2010, **62**(1), 83–99.
- S. Tanga, M. Aucamp and P. Ramburrin, Injectable Thermo-responsive Hydrogels for Cancer Therapy: Challenges and Prospects, *Gels*, 2023, **9**(5), 418–437.
- R. Fan, Y. Cheng, R. Wang, T. Zhang, H. Zhang, J. Li, *et al.*, Thermosensitive Hydrogels and Advances in Their Application in Disease Therapy, *Polymers*, 2022, **14**(12), 2379–2400.
- K. Zhang, K. Xue and X. J. Loh, Thermo-Responsive Hydrogels: From Recent Progress to Biomedical Applications, *Gels*, 2021, **7**(3), 77–94.
- G. Molinaro, J. C. Leroux, J. Damas and A. Adam, Biocompatibility of thermosensitive chitosan-based hydrogels: an in vivo experimental approach to injectable biomaterials, *Biomaterials*, 2002, **23**(13), 2717–2722.
- L. Klouda and A. G. Mikos, Thermo-responsive hydrogels in biomedical applications, *Eur. J. Pharm. Biopharm.*, 2008, **68**(1), 34–45.
- V. H. G. Phan, E. Lee, J. H. Maeng, T. Thambi, B. S. Kim, D. Lee, *et al.*, Pancreatic cancer therapy using an injectable nanobiohybrid hydrogel, *RSC Adv.*, 2016, **6**(47), 41644–41655.
- B. Jeong, S. W. Kim and Y. H. Bae, Thermosensitive sol-gel reversible hydrogels, *Adv. Drug Delivery Rev.*, 2012, **64**, 154–162.
- S. Pardeshi, F. Damiri, M. Zehravi, R. Joshi, H. Kapare, M. K. Prajapati, *et al.*, Functional Thermo-responsive Hydrogel Molecule to Material Design for Biomedical Applications, *Polymers*, 2022, **14**(15), 3126–3170.
- H. Gholizadeh, E. Landh, D. M. Silva, A. Granata, D. Traini, P. Young, *et al.*, In vitro and in vivo applications of a universal and synthetic thermo-responsive drug delivery hydrogel platform, *Int. J. Pharm.*, 2023, **635**, 122777–122789.
- A. Elsherbeny, H. Bayraktutan, U. Can Oz, C. Moloney, J. C. Ashworth, A. M. Grabowska, *et al.*, Responsive Nanomaterial Delivery Systems for Pancreatic Cancer Management, *Adv. Ther.*, 2023, 2300330–2300362.
- C. Y. Gong, P. W. Dong, S. Shi, S. Z. Fu, J. L. Yang, G. Guo, *et al.*, Thermosensitive PEG–PCL–PEG Hydrogel Controlled Drug Delivery System: Sol–Gel–Sol Transition and In Vitro Drug Release Study, *J. Pharm. Sci.*, 2009, **98**(10), 3707–3717.
- K. Wu, L. Yu and J. Ding, Synthesis of PCL-PEG-PCL Triblock Copolymer via Organocatalytic Ring-Opening Polymerization and Its Application as an Injectable Hydrogel – An Interdisciplinary Learning Trial, *J. Chem. Educ.*, 2020, **97**(11), 4158–4165.
- T. R. Hoare and D. S. Kohane, Hydrogels in drug delivery: Progress and challenges, *Polymer*, 2008, **49**, 1993–2007.
- A. C. Marques, P. J. Costa, S. Velho and M. H. Amaral, Stimuli-responsive hydrogels for intratumoral drug delivery, *Drug Discovery Today*, 2021, **26**(10), 2397–2405.
- J. Luo, X. Zhao, B. Guo and Y. Han, Preparation, thermal response mechanisms and biomedical applications of thermosensitive hydrogels for drug delivery, *Expert Opin. Drug Delivery*, 2023, **20**(5), 641–672.
- K. Dutta, R. Das, J. Ling, R. M. Monibas, E. Carballo-Jane, A. Kekec, *et al.*, In Situ Forming Injectable Thermo-responsive Hydrogels for Controlled Delivery of Biomacromolecules, *ACS Omega*, 2020, **5**(28), 17531–17542.
- J. Shi, L. Yu and J. Ding, PEG-based thermosensitive and biodegradable hydrogels, *Acta Biomater.*, 2021, **128**, 42–59.
- S. Salehi, S. M. Naghib, H. R. Garshasbi, S. Ghorbanzadeh and W. Zhang, Smart stimuli-responsive injectable gels and hydrogels for drug delivery and tissue engineering applications: A review, *Front. Bioeng. Biotechnol.*, 2023, **11**, 1104126–1104146.
- B. Khan, A. Arbab, S. Khan, H. Fatima, I. Bibi, N. P. Chowdhry, *et al.*, Recent progress in thermosensitive hydrogels and their applications in drug delivery area, *MedComm: Biomater. Appl.*, 2023, **2**(3), e55–76.
- C. Y. Gong, S. Shi, P. W. Dong, B. Kan, M. L. Gou, X. H. Wang, *et al.*, Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel, *Int. J. Pharm.*, 2009, **365**(1–2), 89–99.
- S. Singh, M. M. Alrobaian, N. Molugulu, N. Agrawal, A. Numan and P. Kesharwani, Pyramid-Shaped PEG-PCL-PEG Polymeric-Based Model Systems for Site-Specific Drug Delivery of Vancomycin with Enhance Antibacterial Efficacy, *ACS Omega*, 2020, **5**(21), 11935–11945.
- P. Grossen, D. Witzigmann, S. Sieber and J. Huwyler, PEG-PCL-based nanomedicines: A biodegradable drug delivery system and its application, *J. Controlled Release*, 2017, **260**, 46–60.
- S. Z. Fu, P. Y. Ni, B. Y. Wang, B. Y. Chu, L. Zheng, F. Luo, *et al.*, Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration, *Biomaterials*, 2012, **33**(19), 4801–4809.
- M. R. Dethe, P. A. H. Ahmed, M. Agrawal, U. Roy and A. Alexander, PCL-PEG copolymer based injectable thermo-sensitive hydrogels, *J. Controlled Release*, 2022, **343**, 217–236.
- K. Miller, J. E. Hsu and L. J. Soslowsky, Materials in Tendon and Ligament Repair, *Compr. Biomater.*, 2011, **6**, 257–279.
- F. Ebrahimi and H. R. Dana, Poly lactic acid (PLA) polymers: from properties to biomedical applications, *Int. J. Polym. Mater. Polym. Biomater.*, 2022, **71**(15), 1117–1130.
- D. Łysik, J. Mystkowska, G. Markiewicz, P. Deptuła and R. Bucki, The Influence of Mucin-Based Artificial Saliva on Properties of Polycaprolactone and Polylactide, *Polymers*, 2019, **11**(11), 1880–1899.
- A. Elwakeel, H. Soudan, A. Eldoksh, M. Shalaby, M. Eldemellawy, D. Ghareeb, *et al.*, Implementation of the Chou-Talalay method for studying the in vitro pharmacodynamic interactions of binary and ternary drug combinations on MDA-MB-231 triple negative breast cancer cells, *Synergy*, 2019, **8**, 100047–100057.
- H. Chen, L. R. Hart, W. Hayes and C. R. Siviour, Mechanical characterisation and modelling of a thermore-



- versible supermolecular polyurethane over a wide range of rates, *Polymer*, 2021, **221**, 123607–123621.
- 31 B. X. Cheng, W. C. Gao, X. M. Ren, X. Y. Ouyang, Y. Zhao, H. Zhao, *et al.*, A review of microphase separation of polyurethane: Characterization and applications, *Polym. Test.*, 2022, **107**, 107489–107499.
- 32 J. Xie, L. Fan, D. Yao, F. Su, Z. Mu and Y. Zheng, Ultra-robust, self-healable and recyclable polyurethane elastomer via a combination of hydrogen bonds, dynamic chemistry, and microphase separation, *Mater. Today Chem.*, 2022, **23**, 100708–100718.
- 33 S. Farah, D. G. Anderson and R. Langer, Physical and Mechanical Properties of PLA, and Their Functions in Widespread Applications-A Comprehensive Review, *Adv. Drug Delivery Rev.*, 2016, **107**, 367–392.
- 34 L. Ranakoti, B. Gangil, S. K. Mishra, T. Singh, S. Sharma, R. A. Ilyas, *et al.*, Critical Review on Polylactic Acid: Properties, Structure, Processing, Biocomposites, and Nanocomposites, *Materials*, 2022, **15**(12), 4312–4331.
- 35 Y. Lin, E. Bilotti, C. W. M. Bastiaansen and T. Peijs, Transparent semi-crystalline polymeric materials and their nanocomposites: A review, *Polym. Eng. Sci.*, 2020, **60**(10), 2351–2376.
- 36 G. Pasparakis and C. Tsitsilianis, LCST polymers: Thermoresponsive nanostructured assemblies towards bioapplications, *Polymer*, 2020, **211**, 123146–123162.
- 37 Q. Zhang, C. Weber, U. S. Schubert and R. Hoogenboom, Thermoresponsive polymers with lower critical solution temperature: from fundamental aspects and measuring techniques to recommended turbidimetry conditions, *Mater. Horiz.*, 2017, **4**(2), 109–116.
- 38 M. T. Cook, P. Haddow, S. B. Kirton and W. J. McAuley, Polymers Exhibiting Lower Critical Solution Temperatures as a Route to Thermoreversible Gelators for Healthcare, *Adv. Funct. Mater.*, 2021, **31**(8), 2008123–2008148.
- 39 P. Stipa, S. Marano, R. Galeazzi, C. Minelli, G. Mobbili and E. Laudadio, Prediction of drug-carrier interactions of PLA and PLGA drug-loaded nanoparticles by molecular dynamics simulations, *Eur. Polym. J.*, 2021, **147**, 110292–110301.
- 40 M. Shabani Samghabadi, A. Karkhaneh and A. A. Katbab, Synthesis and characterization of biphasic layered structure composite with simultaneous electroconductive and piezoelectric behavior as a scaffold for bone tissue engineering, *Polym. Adv. Technol.*, 2023, **34**(4), 1367–1380.
- 41 M. Haider, A. Elsherbeny, J. Jagal, A. Hubatová-Vacková and I. S. Ahmed, Optimization and evaluation of poly (Lactide-co-glycolide) nanoparticles for enhanced cellular uptake and efficacy of paclitaxel in the treatment of head and neck cancer, *Pharmaceutics*, 2020, **12**(9), 1–22.
- 42 D. Paolino, A. Tudose, C. Celia, L. Di Marzio, F. Cilurzo and C. Mircioiu, Mathematical Models as Tools to Predict the Release Kinetic of Fluorescein from Lyotropic Colloidal Liquid Crystals, *Materials*, 2019, **12**(5), 693–716.
- 43 X. Wang, S. S. Venkatraman, F. Y. C. Boey, J. S. C. Loo and L. P. Tan, Controlled release of sirolimus from a multi-layered PLGA stent matrix, *Biomaterials*, 2006, **27**(32), 5588–5595.
- 44 Q. Yu, X. Tang, W. Zhao, Y. Qiu, J. He, D. Wan, *et al.*, Mild hyperthermia promotes immune checkpoint blockade-based immunotherapy against metastatic pancreatic cancer using size-adjustable nanoparticles, *Acta Biomater.*, 2021, **133**, 244–256.
- 45 Y. Fu and W. J. Kao, Drug Release Kinetics and Transport Mechanisms of Non-degradable and Degradable Polymeric Delivery Systems, *Expert Opin. Drug Delivery*, 2010, **7**(4), 429–444.
- 46 T. C. Chou, Drug combination studies and their synergy quantification using the Chou-Talalay method, *Cancer Res.*, 2010, **70**(2), 440–446. Available from: <https://cancerres.aacr-journals.org/cgi/content/full/70/2/440>.
- 47 W. Wang, H. Song, J. Zhang, P. Li, C. Li, C. Wang, *et al.*, An injectable, thermosensitive and multicompartiment hydrogel for simultaneous encapsulation and independent release of a drug cocktail as an effective combination therapy platform, *J. Controlled Release*, 2015, **203**, 57–66.
- 48 N. A. Pham, N. Radulovich, E. Ibrahimov, S. N. Martins-Filho, Q. Li, M. Pintilie, *et al.*, Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers, *Sci. Rep.*, 2021, **11**(1), 1–12.
- 49 A. H. Fischer, K. A. Jacobson, J. Rose and R. Zeller, Hematoxylin and eosin staining of tissue and cell sections, *CSH Protoc.*, 2008, (5), 4986–4989.
- 50 I. Miller, M. Min, C. Yang, C. Tian, S. Gookin, D. Carter, *et al.*, Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence, *Cell Rep.*, 2018, **24**(5), 1105–1112.

